Drugs / KAN-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04248855 | Jan 2020 → Oct 2021 | celiac disease | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05574010 | Nov 2022 → Nov 2024 | celiac disease | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06001177 | Dec 2023 → Jan 2025 | celiac disease | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAN-101 | “Dose 1 KAN-101 Intravenous (IV) infusion” NCT05574010 ↗ |
| Modality | Peptide | “a deaminated gliadin peptide designed to induce immune tolerance to gliadin” PMID 37329900 ↗ Jun 2023 |
| Route | Intravenous | “Part A of the trial was an open-label, single ascending dose study of intravenous KAN-101” PMID 37329900 ↗ Jun 2023 |